MedTrace Logo

Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

NCT01712919 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2014-03-24

No results posted yet for this study

Summary

The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

RADIATION

Intensity-modulated radiotherapy

Patients will be given intensity-modulated radiotherapy(IMRT)

DRUG

Concurrent chemotherapy with paclitaxel and nedaplatin

Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin

BIOLOGICAL

Cetuximab

Patients will be given cetuximab weekly during radiation therapy

Sponsors & Collaborators

  • Jiangsu Cancer Institute & Hospital

    lead OTHER

Principal Investigators

  • Xia He, M.D. Ph.D. · Jiangsu Cancer Institute & Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01712919 on ClinicalTrials.gov